查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2056365

乳癌液態生物檢體市場報告：按產品/服務、循環生物標記、最終用戶和地區分類（2026-2034 年）

Breast Cancer Liquid Biopsy Market Report by Product Service, Circulating Biomaker (Circulating Tumor Cells, Cell-Free DNA, Extracelluar Vesicles, and Others), End User, and Region 2026-2034
出版日期: | 出版商: IMARC | 英文 147 Pages | 商品交期: 2-3個工作天內

價格

2025年，全球乳癌液態生物檢體市場規模達1.73億美元。展望未來，IMARC Group預測，到2034年，該市場規模將達到5.908億美元，2026年至2034年的複合年成長率（CAGR）為14.18%。北美市場是推動該市場成長的主要動力，這得益於非侵入性診斷方法的普及以及政府對癌症篩檢的支持。乳癌發生率的上升、技術的進步以及癌症研究投入的激增是推動市場成長的主要因素。

乳癌液態生物檢體市場趨勢：

乳癌發生率增加

全球乳癌發生率的上升是主要因素之一。例如，根據世界衛生組織（世衛組織）的數據，2022年全球約有230萬名女性被診斷出罹患乳癌，約67萬人死於乳癌。同樣，根據美國國家乳癌基金會的數據，美國八分之一的女性在一生中會被診斷出罹患乳癌。

預計到2024年，將有310,720名女性和2,800名男性被診斷出罹患侵襲性乳癌。由於乳癌仍然是全球女性最常見的癌症之一，因此對早期檢測和監測解決方案（例如液態生物檢體）的需求正在不斷成長。預計這些因素將推動乳癌液態生物檢體市場佔有率在未來幾年內成長。

重點關注早期檢測

乳癌的早期發現能夠顯著改善患者的預後，而液態生物檢體比一些傳統的影像學方法能夠更早發現乳癌。例如，美國國家醫學圖書館發表的報導指出，液態生物檢體（LB）在癌症早期診斷、追蹤腫瘤生長和復發以及預測患者對治療的反應方面展現出巨大潛力。它也已成為現代腫瘤學中不可或缺的工具，因為它能夠實現持續監測，這對於追蹤疾病進展和治療反應至關重要。這些因素進一步推動了乳癌液態生物檢體市場的發展前景。

產品創新

基因測序、分子生物學和生物資訊學領域的創新正在提高液態生物檢體技術的靈敏度、特異性和準確性。例如，2023年11月，專注於DNA定序和晶片技術的Illumina公司開發了一種改進的用於基因組分析的分散式液態生物檢體檢測方法。

新型 TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) 是一種檢測方法，可對血液中的循環腫瘤 DNA (ctDNA) 進行非侵入性、全面的基因組分析 (CGP)。這些進展有助於癌症的早期檢測、治療效果的監測以及抗藥性突變的識別，從而加速液態生物檢體在臨床實踐中的應用，並最終推動乳癌液態生物檢體市場的成長。

目錄

第1章：序言

第2章：調查方法

  • 調查目的
  • 相關利益者
  • 數據來源
    • 主要訊息
    • 二手資訊
  • 市場估值
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第3章執行摘要

第4章：引言

第5章：全球乳癌液態生物檢體市場

  • 市場概覽
  • 市場表現
  • 新冠疫情的影響
  • 市場預測

第6章 市場區隔：依產品及服務分類

  • 試劑組
  • 裝置
  • 服務

第7章 市場區隔：依循環生物標記分類

  • 循環性腫瘤細胞（CTCs）
  • 遊離DNA（cfDNA）
  • 細胞外囊泡（EVs）
  • 其他

第8章 市場區隔：依最終用戶分類

  • 參考實驗室
  • 醫院和醫生檢查室
  • 其他

第9章 市場區隔：依地區分類

  • 北美洲
    • 美國
    • 加拿大
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 俄羅斯
    • 其他
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他
  • 中東和非洲

第10章 SWOT 分析

第11章：價值鏈分析

第12章：波特五力分析

第13章：價格分析

第14章 競爭格局

  • 市場結構
  • 大公司
  • 主要公司簡介
    • Biocept Inc.
    • Bio-Rad Laboratories Inc.
    • F. Hoffmann-La Roche AG
    • Fluxion Biosciences Inc.
    • Guardant Health Inc.
    • Illumina Inc.
    • Menarini Silicon Biosystems（The Menarini Group）
    • NeoGenomics Laboratories Inc.
    • Qiagen
    • Sysmex Europe SE（Sysmex Corporation）
Product Code: SR112026A6047

The global breast cancer liquid biopsy market size reached USD 173.0 Million in 2025. Looking forward, IMARC Group expects the market to reach USD 590.8 Million by 2034, exhibiting a growth rate (CAGR) of 14.18% during 2026-2034. North America dominates the market, driven by the ongoing shift towards non-invasive diagnostic methods and supportive government initiatives for cancer screening. The rising prevalence of breast cancer, technological advancements, and surging investments in cancer research are primarily fueling the market growth.

Breast Cancer Liquid Biopsy Market Analysis:

  • Major Market Drivers: The growing prevalence of breast cancer along with the escalating demand for non-invasive medical procedures is primarily driving the global breast cancer liquid biopsy market demand. In addition to this, the rising consumer awareness towards numerous benefits associated with the liquid biopsy technique, including quicker results, lower cost, minimal health risk, non-invasiveness, etc., is also augmenting the market growth.
  • Key Market Trends: The increasing number of government and private reimbursement policies for breast cancer biopsy and other related medical procedures is creating a positive outlook for the market. Additionally, the emerging trend of personalized therapeutics coupled with the widespread adoption of polymerase chain reaction (PCR) and next-generation sequencing (NGS) for cancer detection will continue to drive the global breast cancer liquid biopsy market in the coming years.
  • Competitive Landscape: Some of the prominent breast cancer liquid biopsy market companies include Biocept Inc., Bio-Rad Laboratories Inc., F. Hoffmann-La Roche AG, Fluxion Biosciences Inc., Guardant Health Inc., Illumina Inc., Menarini Silicon Biosystems (The Menarini Group), NeoGenomics Laboratories Inc., Qiagen, and Sysmex Europe SE (Sysmex Corporation), among many others.
  • Geographical Trends: According to the breast cancer liquid biopsy market forecast report, North America currently dominates the overall market. Breast cancer remains one of the most common cancers affecting women in North America. The increasing number of cases fuels the demand for more effective and less invasive diagnostic tools like liquid biopsies.
  • Challenges and Opportunities: The high costs of developing and validating liquid biopsy tests and regulatory hurdles are hampering the market's growth. However, liquid biopsies can be used to detect minimal residual disease (MRD), where small amounts of cancer remain after treatment and may eventually cause a recurrence. This capability presents a major opportunity in post-treatment monitoring.

Breast Cancer Liquid Biopsy Market Trends:

Increasing Prevalence of Breast Cancer

The increasing global prevalence of breast cancer is one of the primary drivers. For instance, according to the World Health Organization (WHO), in 2022, nearly 2.3 million women were diagnosed with breast cancer, and approximately 670,000 died worldwide. Similarly, according to the National Breast Cancer Foundation, in the United States, 1 out of every 8 women will be diagnosed with breast cancer during their lifetime.

In 2024, an estimated 310,720 women and 2,800 males will be diagnosed with invasive breast cancer. As breast cancer remains one of the most common cancers among women worldwide, the demand for early detection and monitoring solutions, like liquid biopsy, is rising. These factors are expected to propel the breast cancer liquid biopsy market share in the coming years.

Focus on Early Detection

Early detection of breast cancer significantly improves patient outcomes, and liquid biopsy allows for earlier detection than some traditional imaging methods. For instance, according to an article published by the National Library of Medicine, LB has demonstrated potential in diagnosing cancer at an early stage, tracking tumor growth and recurrence, and predicting patient response to therapy. It also enables continuous monitoring, which is essential for tracking disease progression and treatment response, making it an essential tool in modern oncology. These factors further positively influence the breast cancer liquid biopsy market forecast.

Product Innovations

Innovations in genomic sequencing, molecular biology, and bioinformatics are enhancing the sensitivity, specificity, and accuracy of liquid biopsy techniques. For instance, in November 2023, Illumina Inc., a DNA sequencing and array-based technology business, developed an improved version of their distributed liquid biopsy assay for genomic profiling.

The new TruSight Oncology 500 ctDNA v2 (TSO 500 ctDNA v2) is a research assay that allows for non-invasive comprehensive genomic profiling (CGP) of circulating tumor DNA (ctDNA) from blood. These advancements help in early cancer detection, monitoring treatment efficacy, and identifying resistance mutations, which drives the adoption of liquid biopsy in clinical settings, thereby boosting the breast cancer liquid biopsy market growth.

Global Breast Cancer Liquid Biopsy Industry Segmentation:

The research provides an analysis of the key trends in each segment of the global breast cancer liquid biopsy market report, along with forecasts at the global, regional, and country levels from 2026-2034. Our report has categorized the market based on product services, circulating biomarker, and end user.

Breakup by Product Services:

  • Reagent Kits
  • Instruments
  • Service.

Currently, reagent kits account for the majority of the global market share

According to the breast cancer liquid biopsy market outlook, the increasing global incidence of breast cancer has heightened the need for better diagnostic, monitoring, and screening tools. As liquid biopsy becomes more commonly used, the demand for reagent kits that support these tests rises proportionally. Moreover, traditional tissue biopsies are invasive and can cause discomfort and complications. Liquid biopsy offers a non-invasive alternative, which is gaining popularity for both diagnostic and treatment monitoring purposes. This shift is a key driver for reagent kits used in liquid biopsy procedures, such as those for detecting circulating tumor DNA (ctDNA) or circulating tumor cells (CTCs).

Breakup by Circulating Biomarker:

  • Circulating Tumor Cells (CTCs)
  • Cell-Free DNA (cfDNA)
  • Extracellular Vesicles (EVs)
  • Others

According to the breast cancer liquid biopsy market analysis report, CTCs are cancer cells that have shed from the primary tumor into the bloodstream. The presence of CTCs in the blood correlates with disease stage and prognosis. Higher numbers of CTCs are often associated with advanced cancer and poorer outcomes. Moreover, cfDNA consists of small fragments of DNA released from tumor cells (also referred to as circulating tumor DNA or ctDNA) and other cells into the bloodstream.

Moreover, analysis of cfDNA allows for the detection of specific mutations, such as those in the PIK3CA gene, TP53, or ESR1, which can guide treatment choices, especially for targeted therapies. Furthermore, extracellular vesicles (such as exosomes and microvesicles) are small membrane-bound particles released by cells, including cancer cells, into the bloodstream. EVs contain a variety of biomolecules, including proteins, RNA, DNA, and lipids, and can play a role in cell-to-cell communication.

Breakup by End User:

  • Reference Laboratories
  • Hospitals and Physician Laboratories
  • Others

According to the breast cancer liquid biopsy market outlook report, reference labs often have access to the most cutting-edge technologies in liquid biopsy, including next-generation sequencing (NGS) and circulating tumor DNA (ctDNA) analysis. Their advanced infrastructure attracts demand from hospitals and physician labs that do not have these capabilities. Moreover, large hospitals, especially those with dedicated oncology centers, have a high volume of breast cancer patients requiring regular monitoring.

Liquid biopsy offers a less invasive, faster alternative to traditional tissue biopsies for diagnosis, treatment monitoring, and recurrence detection. Furthermore, physical labs are often the first point of care for breast cancer screening. Liquid biopsies provide a more accessible and less invasive option for patients at high risk of breast cancer, allowing for earlier detection and intervention.

Breakup by Region:

  • North America
  • United States
  • Canada
  • Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
  • Latin America
  • Brazil
  • Mexico
  • Others
  • Middle East and Afric.

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America dominates the global market.

According to the breast cancer liquid biopsy market statistics, breast cancer remains one of the most common cancers among women in North America, driving demand for improved diagnostic tools. Moreover, liquid biopsies offer a non-invasive alternative to traditional tissue biopsies, which can be painful, risky, and difficult to perform, especially in advanced cancer cases. As a simple blood test, liquid biopsy is more appealing to patients, contributing to its growing adoption.

Besides this, advances in liquid biopsy technologies, including next-generation sequencing (NGS), PCR-based methods, and improved ctDNA and CTC (circulating tumor cells) detection platforms, have significantly increased the accuracy and sensitivity of these tests. These innovations are driving wider clinical adoption of liquid biopsy for breast cancer diagnosis and monitoring.

Competitive Landscape:

The breast cancer liquid biopsy market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

  • Biocept Inc.
  • Bio-Rad Laboratories Inc.
  • F. Hoffmann-La Roche AG
  • Fluxion Biosciences Inc.
  • Guardant Health Inc.
  • Illumina Inc.
  • Menarini Silicon Biosystems (The Menarini Group)
  • NeoGenomics Laboratories Inc.
  • Qiagen
  • Sysmex Europe SE (Sysmex Corporation)

Key Questions Answered in This Report

  • What was the size of the global breast cancer liquid biopsy market in 2025?
  • What is the expected growth rate of the global breast cancer liquid biopsy market during 2026-2034?
  • What has been the impact of COVID-19 on the global breast cancer liquid biopsy market?
  • What are the key factors driving the global breast cancer liquid biopsy market?
  • What is the breakup of the global breast cancer liquid biopsy market based on the product services?
  • What are the key regions in the global breast cancer liquid biopsy market?
  • Who are the key players/companies in the global breast cancer liquid biopsy market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Breast Cancer Liquid Biopsy Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Product Services

  • 6.1 Reagent Kits
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Instruments
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Services
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7 Market Breakup by Circulating Biomarker

  • 7.1 Circulating Tumor Cells (CTCs)
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Cell-Free DNA (cfDNA)
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Extracellular Vesicles (EVs)
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by End User

  • 8.1 Reference Laboratories
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Hospitals and Physician Laboratories
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by Region

  • 9.1 North America
    • 9.1.1 United States
      • 9.1.1.1 Market Trends
      • 9.1.1.2 Market Forecast
    • 9.1.2 Canada
      • 9.1.2.1 Market Trends
      • 9.1.2.2 Market Forecast
  • 9.2 Asia-Pacific
    • 9.2.1 China
      • 9.2.1.1 Market Trends
      • 9.2.1.2 Market Forecast
    • 9.2.2 Japan
      • 9.2.2.1 Market Trends
      • 9.2.2.2 Market Forecast
    • 9.2.3 India
      • 9.2.3.1 Market Trends
      • 9.2.3.2 Market Forecast
    • 9.2.4 South Korea
      • 9.2.4.1 Market Trends
      • 9.2.4.2 Market Forecast
    • 9.2.5 Australia
      • 9.2.5.1 Market Trends
      • 9.2.5.2 Market Forecast
    • 9.2.6 Indonesia
      • 9.2.6.1 Market Trends
      • 9.2.6.2 Market Forecast
    • 9.2.7 Others
      • 9.2.7.1 Market Trends
      • 9.2.7.2 Market Forecast
  • 9.3 Europe
    • 9.3.1 Germany
      • 9.3.1.1 Market Trends
      • 9.3.1.2 Market Forecast
    • 9.3.2 France
      • 9.3.2.1 Market Trends
      • 9.3.2.2 Market Forecast
    • 9.3.3 United Kingdom
      • 9.3.3.1 Market Trends
      • 9.3.3.2 Market Forecast
    • 9.3.4 Italy
      • 9.3.4.1 Market Trends
      • 9.3.4.2 Market Forecast
    • 9.3.5 Spain
      • 9.3.5.1 Market Trends
      • 9.3.5.2 Market Forecast
    • 9.3.6 Russia
      • 9.3.6.1 Market Trends
      • 9.3.6.2 Market Forecast
    • 9.3.7 Others
      • 9.3.7.1 Market Trends
      • 9.3.7.2 Market Forecast
  • 9.4 Latin America
    • 9.4.1 Brazil
      • 9.4.1.1 Market Trends
      • 9.4.1.2 Market Forecast
    • 9.4.2 Mexico
      • 9.4.2.1 Market Trends
      • 9.4.2.2 Market Forecast
    • 9.4.3 Others
      • 9.4.3.1 Market Trends
      • 9.4.3.2 Market Forecast
  • 9.5 Middle East and Africa
    • 9.5.1 Market Trends
    • 9.5.2 Market Breakup by Country
    • 9.5.3 Market Forecast

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

  • 12.1 Overview
  • 12.2 Bargaining Power of Buyers
  • 12.3 Bargaining Power of Suppliers
  • 12.4 Degree of Competition
  • 12.5 Threat of New Entrants
  • 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

  • 14.1 Market Structure
  • 14.2 Key Players
  • 14.3 Profiles of Key Players
    • 14.3.1 Biocept Inc.
      • 14.3.1.1 Company Overview
      • 14.3.1.2 Product Portfolio
    • 14.3.2 Bio-Rad Laboratories Inc.
      • 14.3.2.1 Company Overview
      • 14.3.2.2 Product Portfolio
    • 14.3.3 F. Hoffmann-La Roche AG
      • 14.3.3.1 Company Overview
      • 14.3.3.2 Product Portfolio
    • 14.3.4 Fluxion Biosciences Inc.
      • 14.3.4.1 Company Overview
      • 14.3.4.2 Product Portfolio
    • 14.3.5 Guardant Health Inc.
      • 14.3.5.1 Company Overview
      • 14.3.5.2 Product Portfolio
    • 14.3.6 Illumina Inc.
      • 14.3.6.1 Company Overview
      • 14.3.6.2 Product Portfolio
    • 14.3.7 Menarini Silicon Biosystems (The Menarini Group)
      • 14.3.7.1 Company Overview
      • 14.3.7.2 Product Portfolio
    • 14.3.8 NeoGenomics Laboratories Inc.
      • 14.3.8.1 Company Overview
      • 14.3.8.2 Product Portfolio
    • 14.3.9 Qiagen
      • 14.3.9.1 Company Overview
      • 14.3.9.2 Product Portfolio
    • 14.3.10 Sysmex Europe SE (Sysmex Corporation)
      • 14.3.10.1 Company Overview
      • 14.3.10.2 Product Portfolio

List of Figures

  • Figure 1: Global: Breast Cancer Liquid Biopsy Market: Major Drivers and Challenges
  • Figure 2: Global: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020-2025
  • Figure 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 4: Global: Breast Cancer Liquid Biopsy Market: Breakup by Product Services (in %), 2025
  • Figure 5: Global: Breast Cancer Liquid Biopsy Market: Breakup by Circulating Biomarker (in %), 2025
  • Figure 6: Global: Breast Cancer Liquid Biopsy Market: Breakup by End User (in %), 2025
  • Figure 7: Global: Breast Cancer Liquid Biopsy Market: Breakup by Region (in %), 2025
  • Figure 8: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 9: Global: Breast Cancer Liquid Biopsy (Reagent Kits) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 10: Global: Breast Cancer Liquid Biopsy (Instruments) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 11: Global: Breast Cancer Liquid Biopsy (Instruments) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 12: Global: Breast Cancer Liquid Biopsy (Services) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 13: Global: Breast Cancer Liquid Biopsy (Services) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 14: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 15: Global: Breast Cancer Liquid Biopsy (Circulating Tumor Cells (CTCs)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 16: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 17: Global: Breast Cancer Liquid Biopsy (Cell-Free DNA (cfDNA)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 18: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 19: Global: Breast Cancer Liquid Biopsy (Extracellular Vesicles (EVs)) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 20: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 21: Global: Breast Cancer Liquid Biopsy (Other Circulating Biomarkers) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 22: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 23: Global: Breast Cancer Liquid Biopsy (Reference Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 24: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 25: Global: Breast Cancer Liquid Biopsy (Hospitals and Physician Laboratories) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 26: Global: Breast Cancer Liquid Biopsy (Other End Users) Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 27: Global: Breast Cancer Liquid Biopsy (Other End Users) Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 28: North America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 29: North America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 30: United States: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 31: United States: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 32: Canada: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 33: Canada: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 34: Asia-Pacific: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 35: Asia-Pacific: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 36: China: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 37: China: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 38: Japan: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 39: Japan: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 40: India: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 41: India: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 42: South Korea: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 43: South Korea: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 44: Australia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 45: Australia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 46: Indonesia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 47: Indonesia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 48: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 49: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 50: Europe: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 51: Europe: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 52: Germany: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 53: Germany: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 54: France: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 55: France: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 56: United Kingdom: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 57: United Kingdom: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 58: Italy: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 59: Italy: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 60: Spain: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 61: Spain: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 62: Russia: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 63: Russia: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 64: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 65: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 66: Latin America: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 67: Latin America: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 68: Brazil: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 69: Brazil: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 70: Mexico: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 71: Mexico: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 72: Others: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 73: Others: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 74: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Sales Value (in Million USD), 2020 & 2025
  • Figure 75: Middle East and Africa: Breast Cancer Liquid Biopsy Market: Breakup by Country (in %), 2025
  • Figure 76: Middle East and Africa: Breast Cancer Liquid Biopsy Market Forecast: Sales Value (in Million USD), 2026-2034
  • Figure 77: Global: Breast Cancer Liquid Biopsy Industry: SWOT Analysis
  • Figure 78: Global: Breast Cancer Liquid Biopsy Industry: Value Chain Analysis
  • Figure 79: Global: Breast Cancer Liquid Biopsy Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Breast Cancer Liquid Biopsy Market: Key Industry Highlights, 2025 and 2034
  • Table 2: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Product Services (in Million USD), 2026-2034
  • Table 3: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Circulating Biomarker (in Million USD), 2026-2034
  • Table 4: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by End User (in Million USD), 2026-2034
  • Table 5: Global: Breast Cancer Liquid Biopsy Market Forecast: Breakup by Region (in Million USD), 2026-2034
  • Table 6: Global: Breast Cancer Liquid Biopsy Market: Competitive Structure
  • Table 7: Global: Breast Cancer Liquid Biopsy Market: Key Players